C6534 H10036 N1720 O2040 S42 (non glycosylated)
Immunoglobulin G4, anti-(human Chemokine receptor CCR5) (humanized monoclonal PRO 140 γ4-chain), disulfide with humanized monoclonal PRO 140 κ-chain, dimer
Leronlimab is in Phase 2b/3 development for HIV treatment.
(Compound details obtained from ChemIDplus Advanced,1 Treatment Action Group Pipeline Report 2021,2 American Medical Association website,3 and ClinicalTrials.gov4)
What is leronlimab?
Leronlimab is anthat is being studied to treat HIV .2
Leronlimab belongs to a group of HIV drugs called.2 CCR5 antagonists block HIV from getting into and infecting certain cells of the . This prevents HIV from multiplying and can reduce the amount of HIV in the body.
Studies indicate that leronlimab may be effective against maraviroc (brand name: Selzentry).5,6that is resistant to
Select clinical trials of leronlimab
On March 30, 2022, the developer’s of leronlimab announced that the U.S. March 30, 2022 press release.7(FDA) placed a partial on the company’s HIV program. The partial clinical hold affects participants who are enrolled in extension trials; participants in these trials will switch to other available treatment. Until the partial clinical hold is lifted, no clinical studies will be initiated or resumed. For more information about the clinical hold, please refer to the drug developer’s
Study Name: NCT00642707
Status: This study has been completed.
Location: United States
Purpose: The purpose of this study was to look at the effectiveness, safety, and drug properties of different doses of leronlimab and compare leronlimab to a . Leronlimab was given as and by .8,9
Selected Study Results: Results published in The Journal of Infectious Diseases (2010) showed that leronlimab had substantial and prolonged activity against HIV. The level of antiviral reponse increased as the total amount of leronlimab administered over the treatment period increased. The greatest antiviral effect was seen with leronlimab 324 mg weekly, producing an average maximum reduction in of 1.65 copies/mL.9
Study Names: (1) PRO 140_CD 01; NCT02175680 and (2) PRO 140_CD 01-Extension; NCT02355184
Status: PRO 140_CD 01 has been completed. The leronlimab HIV program was placed on partial clinical hold. Please refer to the ClinicalTrials.gov record and/or the drug developer’s website for updates on the status of PRO 140_CD 01-Extension.
Location: United States
Purpose: The purpose of the PRO 140_CD 01 study was to evaluate the safety and efficacy of leronlimab monotherapy for the maintenance of . The PRO 140_CD 01-Extension study is evaluating the long-term effectiveness and safety of leronlimab monotherapy for HIV treatment.6,7,10,11
Selected Study Results: Results published in HIV Clinical Trials (2018) showed that in the CD01 study, 23 out of 41 participants (56.1%) maintained viral suppression throughout the 12 week monotherapy treatment phase. Eighteen participants did not maintain suppression during the treatment phase, with a mean time to of 51.3 days since the initiation of leronlimab monotherapy. In the CD01 Extension study, five out of 16 participants experienced viral rebound, with a mean time to rebound of 323 days.6
Study Names: (1) PRO 140_CD 02; NCT02483078 and (2) PRO 140_CD 02 Extension; NCT02990858 and (3) PRO 140_CD02_OpenLabel; NCT03902522
Status: PRO 140_CD 02 has been completed. The leronlimab HIV program was placed on partial clinical hold. Please refer to the ClinicalTrials.gov record and/or the drug developer’s website for updates on the status of PRO 140_CD 02 Extension and PRO 140_CD02_OpenLabel.
Location: United States and Puerto Rico
Purpose: The purpose of the PRO 140_CD 02 study was to look at the safety and effectiveness of using leronlimab with a failing ART regimen for 1 week and then using leronlimab with an optimized ART regimen for 24 weeks. PRO 140_CD 02 Extension is designed to provide eligible participants with continued access to leronlimab. PRO 140_CD02_OpenLabel is a single-arm .7,12–14
Selected Study Results: Results from the CD 02 trial presented at ASM Microbe 2019 showed that 64% of participants who received a single subcutaenous dose of leronlimab had a significant reduction in viral load levels from after 1 week, as compared to 23% of participants who received placebo.15
Study Names: PRO 140_CD03; NCT02859961 and (2) PRO 140_CD03 Extension; NCT05271370
Status: The leronlimab HIV program was placed on partial clinical hold. Please refer to the ClinicalTrials.gov record and/or the drug developer’s website for updates on the status of PRO 140_CD03 and PRO 140_CD03 Extension.
Location: United States
Purpose: The purpose of the PRO 140_CD03 study is to evaluate the safety and effectiveness of leronlimab monotherapy for the maintenance of viral suppression in participants who had undetectable viral load levels on ART. The PRO 140_CD03 Extension study is evaluating the long-term safety and effectiveness of leronlimab monotherapy.4,7,16
Selected Study Results: Preliminary results presented at CROI 2019 indicated that the majority of participants who received higher weekly subcutaneous doses of leronlimab (525 mg and 700 mg) were able to maintain viral suppression.17
For more details on the studies listed above, see the Health Professional version of this drug summary.
What side effects might leronlimab cause?
One goal of HIV research is to identify new drugs that have fewer side effects. The following side effects were observed in some of the studies of leronlimab listed above.NCT00642707:
PRO140_CD 01 (NCT02175680) and PRO 140_CD 01-Extension (NCT02355184):
In this Phase 2a study, the most common side effects that were associated with either placebo or leronlimab included the following: diarrhea, headache, swollen , and . Side effects occurring at or around the injection site were mild and temporary and included hardening of the tissue, pain, and irritation.9
PRO 140_CD 02 (NCT02483078); PRO 140_CD 02 Extension (NCT02990858):
Safety data from 41 participants in the CD_01 study and 16 participants in the CD_01-Extension study found no serious side effects related to leronlimab treatment or study discontinuations due to a side effect. In both studies, mild and temporary local accounted for all of the side effects that were related to the study drug.6,10,11
In the CD_02 study, 52 participants were randomly assigned to either the leronlimab or placebo group. Final results from the study showed that 65.4% of participants experienced at least one side effect and 19.23% of participants had at least one treatment-related side effect. One participant discontinued treatment because of a side effect. No treatment-related serious side effects were reported. Injection site reactions that occurred during the study were mostly mild and went away on their own. Forty participants have enrolled into the CD_02 Extension study.12,13,15
PRO 140_CD03 (NCT02859961):
In the ongoing CD03 trial of leronlimab monotherapy, preliminary data was presented on 226 participants in the 350-mggroup, 115 participants in the 525-mg dose group, and 43 participants in the 700-mg dose group. Thus far, the and severity of side effects have not increased with the dose. Most side effects were mild in intensity and no side effect pattern was observed. None of the serious side effects that occurred were related to leronlimab. The majority of injection site reactions were mild and went away on their own.4,17
Because leronlimab is still being studied, information on possible side effects of the drug is not complete. As testing of leronlimab continues, additional information on possible side effects will be gathered.
Where can I get more information about clinical trials studying leronlimab?
More information about leronlimab-related research studies is available from.
- United States National Library of Medicine. ChemIDplus Advanced: leronlimab. https://chem.nlm.nih.gov/chemidplus/rn/674782-26-4. Accessed June 13, 2022
- Jefferys R. The antiretroviral therapy pipeline 2021. Treatment Action Group Pipeline Report 2021. https://www.treatmentactiongroup.org/wp-content/uploads/2021/07/pipeline_2021_hiv_ARV_final.pdf. Accessed June 13, 2022
- American Medical Association website. Statement on a nonproprietary name adopted by the USAN Council: Leronlimab. https://searchusan.ama-assn.org/undefined/documentDownload?uri=/unstructured/binary/usan/leronlimab.pdf. Accessed June 13, 2022
- CytoDyn, Inc. A Phase 2b/3, multicenter study to assess the treatment strategy of using PRO 140 SC as long-acting single-agent maintenance therapy for 48 weeks in virologically suppressed subjects with CCR5-tropic HIV-1 infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on July 13, 2016. NLM Identifier: NCT02859961. https://clinicaltrials.gov/ct2/show/NCT02859961. Accessed June 13, 2022
- Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC. Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1. Antimicrob Agents Chemother. 2006;50(10):3289-3296. doi:10.1128/AAC.00699-06
- Dhody K, Pourhassan N, Kazempour K, et al. PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection. HIV Clin Trials. 2018;19(3):85-93. doi:10.1080/15284336.2018.1452842
- CytoDyn Inc.: Press release, dated March 30, 2022. CytoDyn announces partial clinical hold of HIV program and full clinical hold of COVID-19 program. https://www.cytodyn.com/investors/news-events/press-releases/detail/598/cytodyn-announces-partial-clinical-hold-of-hiv-program-and. Accessed June 13, 2022
- CytoDyn, Inc. A Phase 2a, randomized, double-blind, placebo controlled study of PRO 140 by subcutaneous administration in adult subjects with human immunodeficiency virus type 1 infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on March 21, 2008. NLM Identifier: NCT00642707. https://clinicaltrials.gov/ct2/show/NCT00642707. Accessed June 13, 2022
- Jacobson JM, Thompson MA, Lalezari JP, et al. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis. 2010;201(10):1481-1487. doi:10.1086/652190
- CytoDyn, Inc. A Phase 2b study to assess suppression of HIV-1 replication following substitution of stable combination antiretroviral therapy with a PRO 140 (monoclonal CCR5 antibody) monotherapy in adult subjects with HIV-1 infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on June 24, 2014. NLM Identifier: NCT02175680. https://clinicaltrials.gov/ct2/show/NCT02175680. Accessed June 13, 2022
- CytoDyn, Inc. Extension of protocol PRO140_CD01 to evaluate long-term suppression of HIV-1 replication following substitution of stable combination ART with PRO 140 (monoclonal CCR5 antibody) monotherapy for additional 160 weeks in adult subjects w/ HIV-1. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 30, 2015. NLM Identifier: NCT02355184. https://clinicaltrials.gov/ct2/show/NCT02355184. Accessed June 13, 2022
- CytoDyn, Inc. A multi-center, randomized, double-blind, placebo-controlled trial, followed by single-arm treatment of PRO 140 in combination with optimized background therapy in treatment-experienced HIV-1 subjects. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on June 24, 2015. NLM Identifier: NCT02483078. https://clinicaltrials.gov/ct2/show/NCT02483078. Accessed June 13, 2022
- CytoDyn, Inc. An extension protocol for subjects who successfully completed PRO140_CD02 study. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 17, 2016. NLM Identifier: NCT02990858. https://clinicaltrials.gov/ct2/show/NCT02990858. Accessed June 13, 2022
- CytoDyn, Inc. A multi-center, two-part, single-arm, open label, 25-week trial with PRO 140 in treatment-experienced HIV-1 subjects. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on April 2, 2019. NLM Identifier: NCT03902522. https://clinicaltrials.gov/ct2/show/NCT03902522. Accessed June 13, 2022
- Dhody K, Kazempour K, Pourhassan N, Maddon PJ. Final results of the pivotal study of PRO 140 SC in heavily treatment-experienced HIV patients. Poster presented at: American Society for Microbiology (ASM) Microbe; June 20-24, 2019; San Francisco, CA. Poster AAR-713. https://content.equisolve.net/_0fabb8b784fee97a4a4b390ab5453a6b/cytodyn/db/193/2464/pdf/CytoDyn+-+ASM+2019+Poster+Presentation+re+CD02_Final.pdf. Accessed June 13, 2022
- CytoDyn, Inc. An extension protocol for virologically suppressed subjects who successfully completed PRO140_CD03 study. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 13, 2022. NLM Identifier: NCT05271370. https://clinicaltrials.gov/ct2/show/NCT05271370. Accessed June 13, 2022
- Dhody K, Kazempour K, Pourhassan N, Maddon PJ. PRO 140 (leronlimab) SC: long-acting single-agent maintenance therapy (SAMT) for HIV-1 infection. Poster presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7, 2019; Seattle, WA. Poster 486. https://2jg4quetidw2blbbq2ixwziw-wpengine.netdna-ssl.com/wp-content/uploads/sites/2/posters/2019/1430_Dhody_0486.pdf. Accessed June 13, 2022
Last Reviewed: June 13, 2022